About Evolva Holding
Evolva Holding develops and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors in Switzerland, United States, Denmark, and internationally.
Expert Collections containing Evolva Holding
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Evolva Holding is included in 1 Expert Collection, including Synthetic Biology.
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Evolva Holding Patents
Evolva Holding has filed 8 patents.
Sugar substitutes, Ion channels, Molecular biology, Medicinal plants, Herbs
Sugar substitutes, Ion channels, Molecular biology, Medicinal plants, Herbs
Latest Evolva Holding News
Sep 28, 2023
Evolva and LEHVOSS sign agreement for distribution of Veri-teTM Resveratrol in over a dozen European countries Evolva Holding SA / Key word(s): Agreement 28-Sep-2023 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. 53 LR Evolva and LEHVOSS sign agreement for distribution of Veri-teTM Resveratrol in over a dozen European countries Reinach, 28 September 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, and LEHVOSS UK Ltd. (“LEHVOSS”), a leading European distributor with technical sales and marketing expertise supplying branded and high quality ingredients to a variety of industries in nutrition, personal care and other market segments, have signed an agreement for the distribution of Evolva’s Veri-teTM Resveratrol in over a dozen European countries for use in dietary supplements through LEHVOSS subsidiaries and expert teams across Europe. Sales from the agreement are expected to amount to around CHF 1.5 million by the end of 2025. Over a dozen European countries are covered under the agreement. It is anticipated that the agreement will generate approximately CHF 1.5 million in sales by the conclusion of 2025. The agreement is further testimony to Evolva’s market expansion activities. Following market launch and successful entry into five South-East Asian countries as well as Brazil with Veri-teTM Resveratrol for use in foods and dietary supplements over the recent past, the agreement with LEHVOSS now also paves the way to strengthen distribution in important European countries. Veri-teTM Resveratrol is the main pillar of Evolva’s Health Ingredients (HI) business and was a key driver for the 14% revenue growth in HI recorded in the first half of 2023. Anne De Vos, Chief Commercial Officer of Evolva, comments: ”We are very excited to strengthen the presence of our Veri-teTM Resveratrol across a wider range of European countries. Veri-teTM Resveratrol is a responsible multi-functional ingredient with proven health benefits supported by a number of clinical studies. We consider LEHVOSS to be an ideal partner for the distribution of Veri-teTM Resveratrol due to its exceptional market capabilities.” Teresita Rudà, Head of Brands and Marketing for LEHVOSS Nutrition adds: “We are thrilled to add this high quality, researched and sustainable brand to our portfolio. We are convinced that Veri-te™ Resveratrol will add strength to our specially selected offer of ingredients across Europe and we look forward to a successful partnership with Evolva.” +41 79 410 81 88 About Veri-teTM Resveratrol Resveratrol is a polyphenolic compound that occurs naturally in plants such as grapes, peanuts, cranberries and other berries, albeit at low concentrations. Evolva’s Veri-teTM Resveratrol is a nature-based high-purity ingredient, made via fermentation, which ensures a stable, traceable and reliable supply. The ingredient is offered in different formats such as a cold-water dispersible or an oil and water-soluble resveratrol and is sold for use in dietary supplements, functional beverages, cosmetics, pharma applications and animal health market About Evolva Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees are dedicated to make the best products that can contribute to health, wellness and sustainability. Find out more at evolva.com and connect with us on LinkedIn . About LEHVOSS Nutrition LEHVOSS Nutrition is a business division of the Hamburg based LEHVOSS Group, dedicated to the marketing and distribution of nutraceutical ingredients and minerals for Food Supplements, Functional Foods and Pet food applications, throughout Europe. Their ingredients’ portfolio covers Women’s Health, Healthy Aging, Weight Management, Beauty Within, Immune Support, Joint Health, Cardiovascular, Cognitive, Gut Health, Sport Nutrition and more. To learn more about LEHVOSS Nutrition visit www.lehvoss-nutrition.com or follow us on LinkedIn. Disclaimer This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. Additional features:
Evolva Holding Frequently Asked Questions (FAQ)
When was Evolva Holding founded?
Evolva Holding was founded in 2004.
Where is Evolva Holding's headquarters?
Evolva Holding's headquarters is located at Duggingerstrasse 23, Reinach.
What is Evolva Holding's latest funding round?
Evolva Holding's latest funding round is PIPE - III.
How much did Evolva Holding raise?
Evolva Holding raised a total of $54.41M.
Who are the investors of Evolva Holding?
Investors of Evolva Holding include Veraison Capital, Nice & Green, Arpida, Aravis Ventures, Wellington Partners and 13 more.
Who are Evolva Holding's competitors?
Competitors of Evolva Holding include Concert Pharmaceuticals, Biosyntia, Viamet Pharmaceuticals, Novira Therapeutics, Catabasis Pharmaceuticals and 13 more.
Compare Evolva Holding to Competitors
Tequesta Marine Biosciences is a specialty pharmaceutical firm that develops small molecule therepeutic drugs for inflammatory conditions.
Oxagen is a biopharmaceutical company that develops small molecule drugs for inflammatory and respiratory diseases.
Stemina Biomarker Discovery is a developer of molecular biomarkers designed to perform diagnosis and treat neurological disorders, including autism spectrum disorders. It offers the discovery, development, and commercialization of molecular biomarkers for drug safety and human health. It provides compound screening and diagnostic development for the pharmaceutical and biotechnology industries. The company was founded in 2006 and is based in Madison, Wisconsin.
Nora Pharmaceuticals, in stealth mode, is a developer of women's reproductive health drugs and devices.
Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.
Total Pharmaceutical Care, Inc. offers home healthcare and infusion therapy services